Bentham Science Logo

Track Your Manuscript:


Current Pharmacogenomics and Personalized Medicine

Formerly: Current Pharmacogenomics

Volume 17, 3 Issues, 2020
ISSN: 1875-6913 (Online)
ISSN: 1875-6921 (Print)
This journal supports open access
Order Your Article Before PrintSubscribe to this Journal

In the current pandemic scenario, publication process of all articles related to Coronavirus will be expedited, for timely publication of much needed research

Aims & Scope

Current Pharmacogenomics and Personalized Medicine (CPPM) is a transdisciplinary, peer-reviewed, biomedical journal that reports new findings and cutting-edge concepts in all areas of pharmacology. Special consideration is given to articles on pharmacogenomics and personalized medicine. CPPM is an accelerator for global personalized medicine and pharmacogenomics, as well as preclinical and clinical pharmacology. Importantly, the journal provides a multi-disciplinary, integrated platform from cell to society to address diagnostics and responsible pharmacogenomics applications in developing countries and the entire range of translational science from bench-to-bedside in various therapeutic areas such as oncology, cardiovascular, neuropharmacology, endocrine diseases, amongst others.

CPPM cooperates with the Ibero-American Network of Pharmacogenetics and the Pacific Rim Association for Clinical Pharmacogenetics and welcomes peer reviewed contributions from authors in any global region.

The journal's scope is defined by four inter-connected aims. First, we are interested in genomics/postgenomics biotechnologies and diagnostics that enable global personalized medicine science (including and beyond pharmacogenomics), as long as they explain person-to-person and population differences in disease susceptibility or response to a health intervention, and can be substantiated. Second, we approach personalized medicine as ‘personalized health interventions’ focusing primarily on drug therapy, but also other interventions such as nutrition, vaccines, surgical devices, emerging cell-based therapies that collectively contribute to healthcare. Third, we strive to integrate molecular and clinical investigation with public policy, global health diplomacy and social studies of biotechnology, that collectively shape postgenomics future(s) and innovation trajectories in life sciences. Fourth, we are interested in all aspects of translational pharmacology from preclinical to clinical applications in any therapeutic area that will advance the practice of medicine for the benefit of patients worldwide including non-communicable diseases as well as infectious diseases in the post- COVID world.

Priority will be given to expert reviews/ mini-reviews and research articles that include original ideas and findings related to the scope and mandate of the journal. Unsolicited submissions are welcomed.

Current Pharmacogenomics and Personalized Medicine

,

Volume 17

-

Number 1



Biography   Open Access



Preface   Open Access



Editorial   Open Access

HLA-B27 is a Risk Factor for Rheumatoid Arthritis: Suggestion for an Evidence-based Update

, 17(1): 7 - 10

Seyyed Amir Yasin Ahmadi, Reza Mohammadrezaei-Khorramabadi, Saber Abbaszadeh, Jafar Rezaian and Farhad Shahsavar*


DOI: 10.2174/1875692117666190408113012


Perspective   Open Access



Review Article   Open Access



Review Article



Research Article   Open Access

Peculiaritie of Distribution of Polymorphic Variants of IL1Β Gene in Patients with Atherosclerosis and Metabolic Syndrome

, 17(1): 32 - 39

Saranchina Y. Vladimirovna*, Rossova N. Aleksandrovna, Khanarin N. Vladimirovich, Kilina O. Yur'evna, Dutova S. Vyacheslavovna and Kulakova T. Sergeevna


DOI: 10.2174/1875692117666190416150346


Research Article   Open Access

Genetic Polymorphisms of CYP2D6: Prevalence in Healthy Kurds

, 17(1): 40 - 47

Muslih Abdulkarim Ibrahim*, Zalina Zahari*, Nurfadhlina Musa and Khoo Boon Yin


DOI: 10.2174/1875692117666190416145331


Abstracts Ahead of Print

There are currently no Abstracts Ahead of Print available for this journal.

Published Contents

Editor's Choice




The Gut Microbiota in Cardiovascular Diseases: From Biomarkers and Potential Targets to Personalized Interventions

, 2018; 16(1): 75 - 85

Yaroslav I. Ashikhmin, Abram L. Syrkin, Andrey A. Zamyatnin Jr.*, Yong Zhang and Philipp Yu. Kopylov*


DOI: 10.2174/1875692116666180511170329




Cardiovascular Pharmacogenomics

, 2017; 15(1): 67 - 80

Valentina Manzo*, Sara Tarallo, Teresa Iannaccone, Maria Costantino, Walter Filippelli and Amelia Filippelli


DOI: 10.2174/1875692115666170503124456



Gender Differences in Response to Therapy for Cardiovascular Diseases

, 2017; 15(1): 14 - 26

Corbi Graziamaria*, Ambrosino Immacolata, Komici Klara, Cellurale Michele, Lombardi Anna and Ferrara Nicola


DOI: 10.2174/1875692115666170508153322



Allele Frequencies of CYP2D6, CYP3A5 and DPYD Genes Polymorphisms in the Healthy Yakut Population

, 2016; 14(1): 50 - 55

Filipp F. Vasilyev, Diana A. Danilova, Vladimir S. Kaimonov, Yana V. Chertovskih and Nadezda R. Maksimova


DOI: 10.2174/1875692114666160801151257




Exome-wide pharmacogenomic analysis of response to thiopurines in inflammatory bowel disease patients

, 2015; 13(1): 61 - 67

William Zabala, Raquel Cruz, Manuel Barreiro-de Acosta, María Chaparro, Julián Panes, Ana Echarri, Maria Esteve, Daniel Carpio, Montserrat Andreu, Esther Garcia-Planella, Eugeni Domenech, Angel Carracedo, Javier P. Gisbert, Francisco Barros and on behalf of EIGA and ENEIDA investigators


DOI: 10.2174/1875692113666150813151413



Open Access Articles

HLA-B27 is a Risk Factor for Rheumatoid Arthritis: Suggestion for an Evidence-based Update

, 2020; 17(1): 7 - 10

Seyyed Amir Yasin Ahmadi, Reza Mohammadrezaei-Khorramabadi, Saber Abbaszadeh, Jafar Rezaian and Farhad Shahsavar*






Mutation Analysis of ABL1 Gene and its Relation to the Achievement of Major Molecular Response in Indonesian Chronic Myeloid Leukemia Patients

, 2020; 17(1): 48 - 54

Reni Widyastuti, Melva Louisa, Ikhwan Rinaldi*, Riki Nova , Instiaty Instiaty and Rizky Priambodo




Genetic Polymorphisms of CYP2D6: Prevalence in Healthy Kurds

, 2020; 17(1): 40 - 47

Muslih Abdulkarim Ibrahim*, Zalina Zahari*, Nurfadhlina Musa and Khoo Boon Yin




Peculiaritie of Distribution of Polymorphic Variants of IL1Β Gene in Patients with Atherosclerosis and Metabolic Syndrome

, 2020; 17(1): 32 - 39

Saranchina Y. Vladimirovna*, Rossova N. Aleksandrovna, Khanarin N. Vladimirovich, Kilina O. Yur'evna, Dutova S. Vyacheslavovna and Kulakova T. Sergeevna







Molecular Mechanism of Metformin Associated Lactic Acidosis (MALA)- an In Silico Exploration

, 2018; 16(3): 199 - 209

Siddiqur Rahman, Tamim Ahsan, Riajul Hossain, Tasnim Ahmed and Abu Ashfaqur Sajib*




Metabolomics-based Approach to Pharmacotherapy Personalization: Advantages and Limitations

, 2018; 16(3): 192 - 198

Dmitry L. Maslov*, Elena E. Balashova, Oxana P. Trifonova and Petr G. Lokhov






Individualized Cancer Therapy, Future Approaches

, 2018; 16(2): 156 - 163

Da-Yong Lu*, Ting-Ren Lu, Bin Xu, Jin-Yu Che, Ying Shen and Nagendra Sastry Yarla






Most Cited Articles

Research Article

Mutation analysis of ABL1 gene and its relation to the achievement of major molecular response in Indonesian chronic myeloid leukemia patients

, 2020; 17(1): 48-54.

Reni Widyastuti, Melva Louisa, Ikhwan Rinaldi*, Riki Nova , Instiaty Instiaty and Rizky Priambodo


DOI: 10.2174/1875692117666190925115852


Research Article

Genetic polymorphisms of CYP2D6: Prevalence in healthy kurds

, 2020; 17(1): 40-47.

Muslih Abdulkarim Ibrahim*, Zalina Zahari*, Nurfadhlina Musa and Khoo Boon Yin


DOI: 10.2174/1875692117666190416145331


Editorial

Hla-b27 is a risk factor for rheumatoid arthritis: Suggestion for an evidence-based update

, 2020; 17(1): 7-10.

Seyyed Amir Yasin Ahmadi, Reza Mohammadrezaei-Khorramabadi, Saber Abbaszadeh, Jafar Rezaian and Farhad Shahsavar*


DOI: 10.2174/1875692117666190408113012


Research Article

Peculiaritie of distribution of polymorphic variants of il1Β gene in patients with atherosclerosis and metabolic syndrome

, 2020; 17(1): 32-39.

Saranchina Y. Vladimirovna*, Rossova N. Aleksandrovna, Khanarin N. Vladimirovich, Kilina O. Yur'evna, Dutova S. Vyacheslavovna and Kulakova T. Sergeevna


DOI: 10.2174/1875692117666190416150346








Most Accessed Articles







Genetic Polymorphisms of CYP2D6: Prevalence in Healthy Kurds

, 2020; 17(1): 40-47.

Muslih Abdulkarim Ibrahim*, Zalina Zahari*, Nurfadhlina Musa and Khoo Boon Yin


DOI: 10.2174/1875692117666190416145331




Editor-in-Chief

Ramón Cacabelos
International Center of Neuroscience and Genomic Medicine
EuroEspes Biomedical Research Center
15165-Corunna
(Spain)
Biography View Full Editorial Board

Journal History

Current Pharmacogenomics was launched in 2003 and later renamed in 2008 as Current Pharmacogenomics and Personalized Medicine.

Related Journals

Related eBooks

eBooks Catalog